Jan 09th 2013 - Edison Investment Research today published a report on quickview entitled "Best-in-class PI". In summary, the report says:
Pivotal Phase III trials have now demonstrated Medivir’s simeprevir to be the best-in-class once daily protease inhibitor (PI) for hepatitis C (HCV). The data should ensure a rapid take up for simeprivir post approval, although partner J&J will –unusually – find itself also marketing its main competitor, Incivek (telaprevir) in the EU. Nevertheless, these data should ensure that Medivir’s drug remains in the race for the real prize, a place in the emerging all oral HCV treatment landscape.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »
